$GMRS

GMR Solutions Inc. (GMRS): Results of Operations and Financial Condition

GMR Solutions Inc. (GMRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ GMR Solutions Inc. Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Reaffirms Full Year 2026 Guidance LEWISVILLE, Texas (August 12, 2026) — GMR Solutions Inc. (“GMR” or the “Company”) (NYSE: GMRS), the nation’s largest provider of em

Original reporting
Published Aug 12, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GMRS
Neutral
medium confidence
Mentioned
$GMRS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GMRSNeutralMed
01

Why it matters

The key tradable elements are the reaffirmed 2026 revenue and Adjusted EBITDA ranges, plus the capital transactions (term loan repayment, preferred stock redemption, and warrant issuance) that affect leverage and funding risk.

02

Market read

This is a primary earnings-style disclosure with guidance ranges and balance-sheet actions, likely driving positioning ahead of the Aug 13 call.

03

What to watch

Investors may underweight the prior-year comparison distortion from unusually strong No Surprises Act collections, and overfocus on headline net loss without separating operating cash generation and balance-sheet improvements.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 12, 2026, ahead of Aug 13 conference call

Background

GMR Solutions filed an SEC 8-K (Item 2.02) with Q2 and six-month results and reaffirmed full-year 2026 guidance, including liquidity and capital structure updates.

Company-level read

Ticker impact

$GMRSNeutralMedium confidence
Context

GMR Solutions reported Q2 2026 net revenue of $1.49B, net loss of $28.3M, and reaffirmed full-year 2026 guidance.

Expected impact

Near-term volatility likely, with upside if guidance is viewed as credible despite lower Adjusted EBITDA.

Evidence & confidence

The filing is a fresh 8-K with updated guidance and detailed operating metrics, but it does not provide a clear beat/miss narrative beyond the stated comparisons and reaffirmation.

Market effects

EMS providers may see read-through on demand durability and reimbursement dynamics, including No Surprises Act claim collections.

Limited direct regional impact; operations are national across air and ground EMS.

Low global relevance; primarily US healthcare services and reimbursement policy exposure.

Counterpoint

Reaffirming guidance may mask underlying margin pressure, since Adjusted EBITDA fell 11.8% year over year while net loss widened versus the prior-year profit.

Key entities

  • GMR Solutions Inc.

    NYSE-listed emergency medical services provider reporting Q2 2026 results and reaffirming full-year 2026 guidance.

  • No Surprises Act claims

    Prior-year collections on claims related to prior years of service created a $74.3M year-over-year difference in changes in revenue estimates.

  • ABL Facility

    Asset-based lending facility referenced for available borrowing capacity of about $696.3M as of June 30, 2026.

Related articles

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

$GMRSMedAI 9/10

Full Transcript: GMR Solutions Q1 2026 Earnings Call - GMR Solutions (NYSE:GMRS)

GMR Solutions (NYSE:GMRS) reported Q1 2026 revenue of $1.46 billion (+6.6% YoY) and adjusted EBITDA of $305 million (+9.7%). The company said its recent IPO leaves net leverage around 3.5x. It cited a 47% rise in 911 nurse navigation calls and nearly $47 million in incremental annualized revenue from new agreements. 2026 guidance targets $5.89–$6.18 billion revenue and high single-digit adjusted EBITDA growth.

$MUHigh

Micron Heads Into Earnings, JPMorgan Sees 2 More Years Of HBM Shortage - Micron Technology (NASDAQ:MU)

JPMorgan analyst Harlan Sur anticipates Micron Technology (MU) will report strong memory pricing in Q4, with revenue, gross margin, and EPS above estimates. Sur forecasts significant price increases for DRAM and NAND, and expects Micron's data-center business to exceed $100B annualized. He predicts November-quarter guidance will beat consensus, with HBM shortages persisting through 2028, maintaining upward pricing pressure. Micron shares were down 3.89% at $1040.18 at the time of publication.